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Aims To determine in a multicentre, multivendor trial the diagnostic performance for perfusion-cardiac magnetic
resonance (perfusion-CMR) in comparison with coronary X-ray angiography (CXA) and single-photon emission
computed tomography (SPECT).
Methods
and results
Of 241 eligible patients from 18 centres, 234 were randomly dosed with 0.01, 0.025, 0.05, 0.075, or 0.1 mmol/kg
Gd-DTPA-BMA (Omniscan
TM
, GE-Healthcare) per stress (0.42 mg/kg adenosine) and rest perfusion study. Coronary
artery disease (CAD) was defined as diameter stenosis 50% on quantitative CXA. Five CMR and eight SPECT
studies (of 225 complete studies) were excluded from analyses due to inadequate quality (three blinded readers
scored per modality). The comparison of CMR vs. SPECT was based on receiver operating characteristic (ROC)
analysis. Perfusion-CMR at the optimal CM dose (0.1 mmol/kg) had similar performance as SPECT, if only the
SPECT studies of the 42 patients with this dose were considered [area under ROC curve (AUC): 0.86+ 0.06 vs.
0.75+ 0.09 for SPECT, P ¼ 0.12]; however, diagnostic performance of perfusion-CMR was better vs. the entire
SPECT population (AUC: 0.67+ 0.05, n ¼ 212, P ¼ 0.013).
Conclusions In this multicentre, multivendor trial, ROC analyses suggest perfusion-CMR as a valuable alternative to SPECT for
CAD detection showing equal performance in the head-to-head comparison. Comparing perfusion-CMR with the
entire SPECT population suggests CMR superiority over SPECT, which warrants further evaluation in larger trials.
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Introduction
The management of patients with known or suspected coronary
artery disease (CAD) is ideally guided by documentation of myo-
cardial ischaemia for optimal planning of medical therapy and/or
revascularization.1 – 4 MR first-pass myocardial perfusion imaging
(perfusion-CMR) has emerged as a sensitive and patient-friendly
diagnostic modality to detect ischaemia, and several single
centre5 –9 and multicentre10,11 studies have yielded excellent
results for CAD detection as defined by conventional coronary
X-ray angiography (CXA). In particular, the high spatial resolution
of perfusion-CMR allows detection of small, even subendocardial
perfusion deficits.5,11,12 In a single centre study, perfusion-CMR
was superior for detection of CAD in comparison with single-
photon emission computed tomography (SPECT),13 and
perfusion-CMR was similar in performance in comparison with
positron emission tomography.5 In patients with acute chest pain,
a normal perfusion-CMR study also had an excellent negative pre-
dictive value of 100% for subsequent diagnosis of CAD or an
adverse outcome.14 However, the diagnostic performance of
perfusion-CMR has not been compared with other established
non-invasive diagnostic techniques in a large multicentre multi-
vendor trial. Accordingly, in 18 centres in Europe and the US,
perfusion-CMR was performed with five CM doses for the detec-
tion of CAD using CXA as the standard of reference and the diag-
nostic performance of perfusion-CMR at the optimum CM dose
was compared with SPECT imaging.
Methods
Study design and patient population
This double-blind, randomized, phase II clinical trial was conducted at
18 centres in Europe and the USA. Eligible patients were those sched-
uled for a conventional CXA and/or a SPECT examination for clinical
reasons. Before study entry, all patients had to agree to undergo all
three tests (CXA, SPECT, and CMR). Patients were included if they
had undergone CXA (being either positive or negative for the pre-
sence of CAD) or if they had undergone positive SPECT with sched-
uled CXA (a positive SPECT was required to guarantee adequate
sensitivity calculations). The order of testing was determined by the
availability of the infrastructure. SPECT was performed as first test in
32% of patients. Both, the CXA and the SPECT examinations must
be performed within 4 weeks before or after the CMR examination.
Exclusion criteria were acute myocardial infarction (MI) (1 week
prior to study enrollment), a history of coronary bypass surgery,
unstable angina pectoris, decompensated heart failure, any interven-
tions on the coronary arteries in the time period between CXA,
SPECT, and the perfusion-CMR examinations, and arrhythmias (con-
sidered to compromise quality of CMR imaging such as atrial fibrillation
or frequent ectopic beats of .20 min21). Patients in stable condition
with a history of MI and/or percutaneous coronary interventions were
not excluded from the study (see also Table 1). Additional exclusion
criteria were any contraindications for adenosine (second or third
AV-block, sick sinus syndrome, symptomatic bradycardia, severe
asthma bronchiale or obstructive pulmonary disease), CM (known
allergy), or CMR examination (implanted electronic devices, metallic
foreign bodies in the eye, severe claustrophobia, and others according
local regulations and manufacturer’s recommendations). For the CMR
examination, all patients were randomly assigned (randomization over
all subjects, not balanced by centre, using ClinPro/LBL system, Inde-
pendent Review Center, GE Healthcare, USA) to one of five dose
groups (0.01, 0.025, 0.05, 0.075, and 0.1 mmol/kg per stress and rest
injection) of a conventional extracellular CM (Gd-DTPA-BMA, Omni-
scan
TM
, GE Healthcare). (For more details on randomization, see Sup-
plementary material online, Appendix in the online version of the
article). For the patients having SPECT as their second or third
examination (i.e. not first examination¼unbiased SPECT population;
n ¼ 153), a sub-analysis was performed. The study was conducted
according to the Declaration of Helsinki, the principles of Good Clini-
cal Practice, and was approved by the Health Authorities and the local
Ethics Committee of each participating institution. All patients gave
written informed consent before study participation.
Efficacy measures
For CAD definition a 50% diameter stenosis in two orthogonal
planes (75% area reduction) on quantitative coronary angiography
was used as in previous studies5,11,15 present in 1 coronary artery.
Quantitative assessment of stenosis severity was performed by a
blinded reader in the core laboratory (Cleveland Clinic Foundation,
Cleveland, USA). Only vessels of 2 mm diameter were considered
for definition of CAD, since smaller vessels are rarely revascularized
(e.g. no stents available for ,2 mm vessels). Vessels with a history
of percutaneous coronary interventions performed successfully prior
to study entry (i.e. residual stenosis of ,50% diameter reduction on
quantitative CXA of the present study) were not defining the presence
of CAD (even though such patients had a known positive history of
CAD). The comparison of perfusion-CMR vs. SPECT for CAD detec-
tion was performed by means of receiver operating characteristic
(ROC) analyses16–18 using CXA as the reference. Additional ROC
analyses were performed in patients with multivessel disease (MVD)
and in the gated-SPECT population.
Another efficacy measure was the accuracy (proportion of correct
diagnoses per patient) for CAD detection by perfusion-CMR for the
five CM doses (for details, see Supplementary material online,
Appendix).
Cardiac magnetic resonance examination
In 1.5 T scanners (Siemens: 8, GE Healthcare: 7, Philips: 3), a breath-
hold MR first-pass perfusion examination was performed. Three short-
axis slices of 8–10 mm thickness were acquired every heart beat at
1/4, 1/2, and 3/4 of the left ventricular (LV) long axis to evenly space
the slices along the long axis. The pulse sequences of all vendors
used a non-slice selective 908-preparation, a saturation—read-out
delay time of ~120 ms, and read-out was achieved by a fast
gradient-echo sequence (with an echo-planar component where
available, whereas parallel imaging was not allowed) yielding a spatial
resolution of 2–3  2–3 mm. Stress data were acquired following
3 min of adenosine (0.14 mg/min/kg intravenous). For the accuracy
evaluation, a second CM injection was performed 20 min after the
stress study allowing for a rest perfusion study (for details see Sup-
plementary material online, Appendix). These additional acquisitions
should enable differentiation between ischaemia and scar tissue, but
these aspects are not specifically addressed in the current report.
CMR data were analysed visually by three blinded readers in an inde-
pendent core laboratory (Independent Review Center, GE Healthcare,
former Nycomed Amersham Imaging, Princeton, USA). All readers
were experts in CMR and were blinded with respect to clinical infor-
mation, the results of the other tests, as well as the order, in which
these tests were performed. A 16-segment model (17-segment
model19 minus the apical segment) was applied, since the vessels
supplying the apex are ,2 mm in diameter in most cases.20
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Accordingly, no long axis acquisition for the apex was acquired.21,22
The stress perfusion data were analysed by ROC curves in order to
assess test sensitivity and specificity simultaneously (without such a
simultaneous specificity assessment, a high sensitivity and accuracy
would be obtained simply by performing a highly sensitive reading in
this population with relatively high disease prevalence).16,17 For the
ROC analysis, the extent of CAD, i.e. the extent of perfusion abnorm-
alities, was assessed on the stress perfusion data by grading the per-
fusion deficits in each of the 16 segments as abnormal with high
confidence (3; defined as myocardium being black at the peak
bolus), or abnormal with low confidence (2; myocardium being dark
grey), or normal with low confidence (1; myocardium being light
grey), or normal with high confidence (0; myocardium being bright;
Figure 1A–C ). Additional criteria indicative for true hypoperfusion vs.
artifacts were subendocardial signal reduction persisting longer than
the CM first-pass through the LV cavity, signal reduction in several
slices and neighbouring regions, and absence of breathing motion
and triggering artifacts during CM first-pass. For each patient, the grad-
ings of all 16 segments were then summed up and the resulting scores
of the three readers were averaged. These summed scores of the
stress perfusion-CMR data (representing extent and severity of per-
fusion abnormalities) were analysed by ROC curves. If all three
readers assessed 1 segment as non-diagnostic in a patient with all
other segments normal, this patient was excluded from analyses result-
ing in a drop-out rate of 2.2% (five cases) of the entire study popu-
lation (Figure 2). In order to keep as many examinations in the trial
as possible (i.e. to avoid a selection bias towards high-quality data),
only those examinations were excluded, in which all three readers
found non-diagnostic segments (if only one or two readers found
non-diagnostic segments, the readings of these readers were excluded
for averaging the scores, but the examination was kept within the ana-
lyses). During the localization procedure of the CMR study, functional
imaging of the left ventricle was performed, but these functional images
were not presented to the blinded readers.
Single-photon emission computed tomography
examination
Stress and rest SPECT examinations were performed according to
generally accepted guidelines19 on machines of different vendors
(two or three head cameras) with 99mTc- or 201Tl-tracers, adenosine
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Demographics of population available for safety evaluation
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5
0.01 (mmol/kg) 0.025 (mmol/kg) 0.05 (mmol/kg) 0.075 (mmol/kg) 0.10 (mmol/kg)
Number 45 50 48 45 45
Male sex—no (%) 32 (71.1) 40 (80.0) 33 (68.8) 33 (73.3) 32 (71.1)
Age—year
Mean+ SD 61.3+9.4 60.6+10.1 59.7+10.3 61.3+10.8 60.5+10.6
Range 43.8–79.6 38.6–82.3 36.1–79.9 41.1–81.0 39.7–78.2
BMI—kg/m2
Mean+ SD 27.6+3.6 26.7+4.2 27.5+4.4 27.6+4.3 27.4+3.9
Range 21.0–36.0 19.0–39.0 19.0–38.0 16.0–42.0 20.0–38.0
Angina pectoris—n (%) 38 (84) 38 (76) 38 (79) 37 (82) 36 (80)
Hypertens.—n (%) 35 (78) 35 (70) 32 (67) 31 (69) 28 (62)
MI—n (%) 19 (42) 24 (48) 14 (29) 17 (38) 16 (36)
PCI—n (%) 12 (27) 20 (40) 14 (29) 16 (36) 10 (22)
CHF—n (%) 6 (13) 4 (8) 6 (13) 7 (16) 8 (18)
QCA—n (%) 45 (100) 49 (98) 47 (98) 44 (98) 45 (100)
CAD—n (%) 35 (78) 41 (84) 36 (77) 32 (76) 33 (73)
MVD—n (%) 20 (44) 32 (65) 22 (47) 20 (48) 20 (44)
LM—n (%) 1 (2) 2 (4) 1 (2) 2 (5) 2 (4)
LAD—n (%) 22 (49) 35 (71) 18 (38) 25 (60) 25 (56)
LCX—n (%) 17 (38) 24 (49) 20 (43) 18 (43) 12 (27)
RCA—n (%) 23 (51) 31 (63) 23 (49) 16 (38) 20 (44)
Any drugs—n (%) 44 (98) 49 (98) 47 (98) 42 (93) 45 (100)
Beta-blockers—n (%) 30 (67) 37 (74) 38 (79) 36 (80) 37 (82)
Statins—n (%) 36 (80) 34 (68) 34 (71) 27 (60) 30 (67)
ACEI—n (%) 21 (47) 29 (58) 21 (44) 23 (51) 20 (44)
Diuretics—n (%) 9 (20) 12 (24) 13 (27) 10 (22) 5 (11)
Ca-CB—n (%) 13 (29) 11 (22) 8 (17) 10 (22) 4 (9)
Antithromb.—n (%) 34 (76) 42 (84) 40 (83) 34 (76) 38 (84)
One patient received 0.037 mmol/kg Gd-DTPA-BMA and is therefore not represented in this table (but was included in the safety analysis and in Figure 2: dose group 4).
BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary intervention; QCA, quantitative coronary angiography; CAD, coronary artery disease; MVD,
multivessel disease; LM, left main; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; ACEI, angiotensin-converting
enzyme inhibitors; Ca-CB, calcium channel blockers.
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dose as for perfusion-CMR, or physical stress, and using 1 or 2 days
protocols. Gated-SPECT using 99mTc-tracers was strongly rec-
ommended, but ungated acquisitions and/or 201Tl-tracers were
accepted if part of the performing institution’s clinical routine. Three
blinded readers, all experts on SPECT (and not identical with the
CMR readers) analysed the SPECT data visually using a core laboratory
(Beacon Bioscience, Inc., Doylestown, USA). All readers were blinded
with respect to clinical information, the results of the other tests, as
well as the order, in which these tests were performed. Each reader
was presented with 10–12 short-axis as well as 6–9 vertical and
horizontal long-axis images for both, stress and rest condition (Figure
1F–K ). Gated-SPECT data were also presented to the readers, if
they had been acquired. On the same 16-segment model used for
CMR, perfusion deficits were graded in each segment as fully reversible
(3), partially reversible (2), fixed defect (1), or normal (0), and scores
were calculated as for the CMR analyses. Patients with 1 segment
graded as non-diagnostic were treated as for the CMR examination,
resulting in 3.6% (eight cases) excluded from the analyses (Figure 2).
According to the CAD definition on CXA (not considering stenoses
in ,2 mm vessels), pure apical ischaemia was not considered a
finding, which defines the presence of CAD.
Safety analysis
Measures of safety included physical findings obtained 1–36 h before
and 24 h after the first CM injection. Vital signs (heart rate, blood
pressure, oxygen saturation), respiratory rate, and body temperature
were documented 0–2 h before the first CM injection and at prede-
fined intervals during the CMR examination and up to 24 h later.
12-lead ECG’s were acquired 0–2 h before the first CM injection
and at 1, 2, and 24 h later. Two-lead ECG’s were acquired at
predefined intervals during the CMR examination. Samples for serum
chemistry (including creatine kinase, aspartate and alanine aminotrans-
ferase, lactate dehydrogenase, creatinine, urea nitrogen, and others)
and hematology (including hemoglobin, red blood cell count, white
blood cell count and differential, platelet count, and others) were col-
lected 0–36 h before and 24 h after the first CM injection. Safety data
were assessed using a core laboratory for ECG and blood samples.
Statistical analysis
The main efficacy outcome was the comparison of perfusion-CMR at
best CM dose vs. SPECT using ROC analysis. Additional study out-
comes were performance of CMR in MVD patients and CMR compari-
son vs. gated-SPECT. For the comparison of perfusion-CMR vs. SPECT
by ROC analysis, estimates suggested a required sample size of ~184
patients to yield an 90% power to detect a difference in the area
under the ROC curve (AUC) of 0.15 (0.70 vs. 0.85 for SPECT and
CMR, respectively) at a one-sided P-value of 0.05.18 ROC analyses
were performed for both, CMR and SPECT on a patient basis in
order to test the diagnostic performance of CMR and SPECT over
the entire range of the summed scores calculated as the average
scores of all three readers (Rockit 0.9.1 Beta). AUCs (as area+ SE)
for CMR and SPECT were compared by a univariate z-score test
(null hypothesis: data sets arose from binormal ROC curves with
equal areas beneath them) taking correlation of the CMR and
SPECT data into account (repeated measurements). Owing to the
low performance of the doses 0.075 mmol/kg (see Figure 3A and
which is also in line with published data),11 statistics were performed
for CMR at the 0.1 mmol/kg dose only (head-to-head comparison
and vs. entire SPECT population). Performance in MVD patients
(2–3 vessel disease) was analysed after exclusion of patients with
single vessel disease. Since the SPECT study must be positive if per-
formed first (which could introduce a bias towards false positives),
SPECT performance (AUC) was also calculated for SPECT being the
second or third test (unbiased SPECT population).
The agreement rate between the independent CMR and SPECT
readers was analysed by the k coefficient. All tests were two-sided
and a P-value ,0.05 was considered statistically significant. For statistical
comparisons of effect of CM dose on accuracy of perfusion-CMR vs.
CXA see Supplementary material online, Appendix in the online version.
Results
Patient characteristics
From the 241 patients enrolled during 12 months, 234 entered the
safety analysis (patients dosed). Of the seven patients not receiving
Figure 1 An example of a 47-year old patient is shown 2 months after successful stenting of the left anterior descending coronary artery and
mild angina. The perfusion-CMR study during hyperemia (at 0.1 mmol/kg Gd-DTPA-BMA) demonstrates a perfusion deficit in the subendocar-
dium of the lateral wall (B/C; arrow heads) appreciated by all three readers (mean score of 13; scores of readers 1–3: 15/9/15). Single-photon
emission computed tomography in this patient was positive for the presence of CAD for one reader (mean score: 2; scores of readers 1–3: 0/6/
0). Coronary X-ray angiography demonstrated a significant stenosis in the circumflex coronary artery (D, arrow). Perfusion in the anterior wall
was assessed correctly by both techniques (normal perfusion) despite a stent in the left anterior descending coronary artery
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Figure 2 Flow chart demonstrating number of eligible patients and reasons for drop-out per dose group. CM: contrast medium (Gd-DTPA-BMA); CXA: coronary X-ray angiography; Pats:
patients
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CM, two refused informed consent (cancellation of given consent),
one had a contraindication to receive adenosine, one experienced
claustrophobia, in two patients invasive X-ray coronary angiogra-
phy was cancelled, and in one patient the procedure during
the MR study was incorrect. Evaluable CXA and correctly per-
formed perfusion-CMR studies were available in 228 patients.
Since three patients had no SPECT study, 225 patients were avail-
able for the perfusion-CMR vs. SPECT comparison. From these
225 patients, 5.8% (13 patients) had either non-evaluable
perfusion-CMR (five patients; 2.2%) and/or SPECT examinations
(eight patients; 3.6%, see also Figure 2). Of all study participants,
73% were male, 77% had CAD, and 31% had a history of percu-
taneous coronary interventions. Further demographics are given
in Table 1.
Comparison of perfusion-cardiac
magnetic resonance at the highest CM
dose to single-photon emission computed
tomography using receiver operating
characteristic analysis
Head-to-head analysis
This comparison showed no superiority of perfusion-CMR over
SPECT (Figure 3B, AUC 0.86+0.06 for CMR vs. 0.75+0.09 for
SPECT, P ¼ 0.12, n ¼ 42 for both, CMR and SPECT) for the
dose of 0.1 mmol/kg, which yielded the best performance for
perfusion-CMR as shown in Figure 3A (largest AUC for
0.1 mmol/kg). From the perfusion-CMR ROC curve in Figure 3B,
it can be seen that, for example, a sensitivity for CAD detection
Figure 3 (A) Shows the diagnostic performance (receiver operating characteristics) for the different contrast medium doses ranging from
0.01 to 0.10 mmol/kg Gd-DTPA-BMA. At the highest dose of 0.10 mmol/kg (thick line, dose 5), best performance is achieved, which is com-
pared vs. single-photon emission computed tomography in (B) (head-to-head comparison) showing no significant difference in the area under
the receiver operating characteristic curve (0.86+ 0.06 vs. single-photon emission computed tomography with 0.75+ 0.09, P ¼ 0.12). Similarly,
for the 2–3 vessel disease population in (C), no significant difference between the two techniques is observed in the head-to-head comparison
(P ¼ 0.09). When comparing the perfusion-CMR performance vs. the entire single-photon emission computed tomography population in (D),
the area under the receiver operating characteristic curve for CMR is larger than for single-photon emission computed tomography
(0.86+ 0.06 vs. 0.67+ 0.5, P ¼ 0.013). Difference between perfusion-CMR and gated-single-photon emission computed tomography did
not reach statistical significance. For multivessel disease in (E), performance of perfusion-CMR is superior vs. the entire multivessel disease
single-photon emission computed tomography population (area under the receiver operating characteristic curve: 0.89+0.06 vs.
0.70+ 0.5, P ¼ 0.006). The performance of perfusion-CMR in this trial is in good agreement with an earlier smaller multicentre single-vendor
trial as shown in (F ) assessing the doses of 0.10 and 0.05 mmol/kg (thin dotted lines, Giang et al.11). Numbers indicate mean+ SE of the area
under the receiver operating characteristic curve
Multicentre perfusion-CMR trial 485
of 85% (95% CI: 69–93%), which is deemed clinically relevant, cor-
responds to a specificity of 67% (95% CI: 35–89%). In the MVD
population (2–3 vessel disease), there was also no superiority
for CMR (0.89+ 0.06 vs. 0.78+0.09 of SPECT, P ¼ 0.09,
n ¼ 31, for dose 0.1 mmol/kg, Figure 3C).
Comparison vs. entire single-photon emission computed
tomography population
When comparing perfusion-CMR at 0.1 mmol/kg vs. the entire
SPECT population (Figure 3D), the ROC analysis demonstrates a
better performance for perfusion-CMR (AUC: 0.86+ 0.06, n ¼
42) vs. SPECT (n ¼ 212, AUC: 0.67+0.05, P ¼ 0.013 vs. CMR).
The CMR performance at 0.1 mmol/kg was also superior in the
MVD population (n ¼ 32 and 161 for CMR and SPECT, respect-
ively, AUC: 0.89+ 0.06 vs. 0.70+0.05, P ¼ 0.006, Figure 3E).
Gated-SPECT was performed in 42% (n ¼ 95) of all SPECT
studies yielding an AUC of 0.75+ 0.08 (not different vs. ungated
SPECT: AUC 0.65+0.06, P ¼ 0.12, and not different vs.
perfusion-CMR: AUC 0.86+ 0.06, P ¼ 0.18, Figure 3D). For CMR
at the CM doses of 0.01, 0.025, 0.05, 0.075 mmol/kg, the visual
inspection of the ROC curves shows similar AUCs (0.69+0.09,
0.60+0.14, 0.64+ 0.10, 0.60+ 0.09, respectively) as for the
SPECT population (0.67+ 0.05, Figure 3A).
The study design requiring a positive SPECT result in patients
undergoing SPECT as the first examination could introduce a
bias towards false-positive SPECT studies. In the 153 patients
with SPECT being the second or third examination, i.e. SPECT
did not influence the referral for CXA (unbiased SPECT popu-
lation), AUC for SPECT was 0.67+ 0.05, which is identical to
the entire SPECT population (also, the CMR result in these 153
patients did not influence the referral for CXA since the patients
had to be scheduled for CXA before study enrollment). The
portion of CAD in the population with SPECT first was 64%
(46/72) and was 82% (125/153) for those with SPECT as second
or third study.
A comparison of the five CM dose groups for accuracy of
perfusion-CMR (proportion of correct diagnoses vs. CXA)
yielded the lowest dose as inferior to the other doses (overall
P, 0.001; for details see Supplementary material online,
Appendix).
Reader agreement
The quality of the 225 CMR data sets was adequate with only 2.2%
(five patients) having non-evaluable perfusion-CMR. For dose
group 5 (0.10 mmol/kg), one patient (out of 45 patients) was
non-evaluable by all three readers (2.2%). Reader 1 (R1) achieved
80% correct diagnoses (after elimination of another eight cases),
whereas reader 2 (R2) and reader 3 (R3) achieved similar accu-
racies of 73 and 78%, respectively (with elimination of another
three patients by R3). Agreement was best between R2 and R3
(k ¼ 0.39). Overall, the k values for the CMR studies were fair
with 0.32 (R1 vs. R2), 0.30 (R1 vs. R3), and 0.39 (R2 vs. R3),
whereas for the SPECT studies, the k values were 0.47 (R1 vs.
R2), 0.58 (R1 vs. R3), and 0.48 (R2 vs. R3). The CMR data
quality was similar for the three different perfusion territories as
indicated by the similar AUCs for detection of stenoses in the
left anterior descending (10 segments assigned), left circumflex
(two segments assigned), and right coronary artery (four segments
assigned) of 0.68+0.08, 0.72+0.09, and 0.70+0.08. It is well
known that vascular anatomy shows individual differences from
patient to patient (e.g. left or right coronary artery dominance)
which is an explanation for the lower AUCs for vessel-based ana-
lyses vs. patient-based analyses.
Safety
In the study, no deaths and no serious adverse events (AE)
occurred. Twenty of 23 AE were mild and the only severe AE
was angina pectoris, which was not related to CM and resolved
within minutes. Angina was the most commonly reported AE
occurring in three patients, followed by chest pain (2), flushing
(2), and hyperpnea (1), which were primarily considered to be
due to the adenosine administration. All 23 AE resolved and
none was skin-associated (except flushing during adenosine infu-
sion and one haematoma at the site of the intravenous line).
No AE resulted in subject withdrawal. The safety profile of
Gd-DTPA-BMA was comparable across all dose groups in this
study and was consistent with the known excellent safety profile
of most CMs used for CMR. No clinically significant trends or
tendencies were noted in the biochemistry and hematology
values over time. There were no 12 lead ECGs available directly
after adenosine infusion. For the time points at 1, 2, and 24 h
after first CM injection, there were no clinically relevant mean
changes from baseline of any ECG-parameter (PR, QRS, QTc,
and RR), which is well in line with other studies on adenosine
administration.23
Discussion
Early detection of myocardial perfusion abnormalities is crucial for
an optimal management of patients with suspected CAD and could
potentially reduce the rate of fatal MIs.24 In this prospective, ran-
domized, multicentre study, a high diagnostic performance of
perfusion-CMR for the detection of CAD in 2 mm coronary
vessels was found at a CM dose of 0.1 mmol/kg, which was
equal to SPECT in the head-to-head comparison. At this CM
dose, the diagnostic performance of perfusion-CMR was superior
vs. SPECT imaging when comparing with all 212 SPECT studies, i.e.
gated and ungated SPECT combined.
Perfusion-cardiac magnetic resonance
and single-photon emission computed
tomography: comparison with previous
studies
MR-IMPACT is the largest multicentre perfusion-CMR study per-
formed so far, and even more important, it also evaluates its test
performance in a multivendor design, which is expected to
reflect true diagnostic performance of widely applied
perfusion-CMR more appropriately than single centre, single
vendor studies. Similar considerations also apply for SPECT,
where for example slightly less than half of all studies were per-
formed with ECG-gating according their clinical routine. Diagnostic
performance of perfusion-CMR was high with an AUC of 0.86 in
this 18 centre, multivendor trial, while performance was as high
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as 0.91 in a previous smaller three centre, single-vendor trial.11 It is
not surprising that high data quality is more difficult to preserve
with a higher number of participating sites and involving various
machine types, but more accurately reflects the routine clinical
application of perfusion-CMR. Therefore, the goal was to homo-
genize the most important CMR imaging parameters for the differ-
ent vendors (which is important since standardization for CMR is
less advanced than for SPECT). The current CMR results are in
line with earlier single-vendor CMR findings with best results at
0.1 mmol/kg,11 although the current study cannot exclude a poten-
tial further increase of performance at doses higher than 0.1 mmol/
kg. The proposed perfusion-CMR approach meets several aspects
of an optimal perfusion test. The perfusion-CMR examination is
short (1 h) and safe, it lacks ionizing radiation, and the CM is
well tolerated. Further, MR-IMPACT indicates that perfusion-CMR
allows to study myocardial perfusion after interventions since
signal response in the myocardium is not affected by stents
located at the epicardium (see also Figure 1). Once hypoperfusion
is detected by perfusion-CMR, additional information can be
obtained by late enhancement CMR on whether hypoperfusion
is caused by scar tissue.25–28 Therefore, a comprehensive
work-up of patients with CAD in the future by CMR will most
likely consist of a combined perfusion and late enhancement study.
A comparison of the current SPECT results determined in 212
patients (all with CXA as reference) from 18 centres with one of
the largest multicentre 99mTc-based SPECT studies published so
far15 including 112 patients (all with CXA) from seven centres
can be made. Their sensitivity and specificity of 78 and 44%,
respectively, is located on the ROC curve of the current SPECT
study. Very close to the current ROC curve is the sensitivity and
specificity of 87 and 36%, respectively, obtained in another multi-
centre SPECT study using 99mTc-sestamibi (and no attenuation
and scatter correction).29 Similar sensitivities of 77–85% and spe-
cificities of 50–58% have also been reported for other multicentre
SPECT trials.30,31 Thus, it can be concluded that the current
SPECT results are in line with previous reports, and this holds
despite a considerably larger number of participating sites in the
present study. This high agreement between the performance of
the entire SPECT population of the current study with that of pre-
vious multicentre SPECT studies supports the comparison of the
perfusion-CMR results not only with the dose group 5 results
(head-to-head comparison), but also with the results of the
entire SPECT population. In support of the current study results,
a recent smaller single centre study demonstrated superiority of
perfusion-CMR over SPECT.13
Limitations of the study
It is important to note that gated-SPECT was not available in
approximately half of patients. Perfusion-CMR did not outperform
gated-SPECT with regard to CAD detection (Figure 3D; the
reduced sample size for this subanalysis may partly explain the
lack of statistical significance). Similarly, the higher AUC of
gated-SPECT32,33 did not reach statistical significance over ungated-
SPECT. Therefore, larger multicentre trials are warranted to
confirm the trend of perfusion-CMR superiority over gated-SPECT.
The apical segment 17 was not included in the analysis, since the
aim was to detect stenosed vessels suitable for revascularization,
i.e. with a minimal diameter of 2 mm. Assuming the apex to rep-
resent a 17th of the LV myocardial mass translates into a vessel
diameter of 0.8 mm,20 thus, detection of pure apical ischaemia
would add potential false positives to both, perfusion-CMR and
SPECT (since stenoses in vessels ,2 mm on quantitative CXA
were not considered to define CAD). On the other hand, the sen-
sitivity for detection of any small ischaemic territory by both,
SPECT and perfusion-CMR could be underestimated by applying
this CAD definition. Finally, a pure apical ischaemia present in
segment 17 only is assumed to be rare, although data in the litera-
ture on occurrence and diagnostic relevance of isolated apical
ischaemia is lacking.
In the current study patients with decompensated heart failure,
after bypass surgery, and with significant arrhythmias were
excluded, and thus, statements cannot be made for these patient
populations. Finally, in MR-IMPACT diagnostic performance of
perfusion-CMR and SPECT was determined in patients undergoing
CXA and therefore could differ in a population at a lower risk for
CAD, e.g. when applied for exclusion of CAD in a screening
setting. Also, the quantitative assessment of stenosis degree has
its limitations to be used as a standard of reference, since myocar-
dial perfusion is not only determined by epicardial coronary ste-
noses, but also by collateral flow and microcirculatory conditions.
Conclusions
In the MR-IMPACT, the ROC analyses suggest, that perfusion-CMR
at 0.1 mmol/kg CM is a valuable technique for CAD detection in
vessels of 2 mm or larger. Thus, in specialized centres
perfusion-CMR may be considered as an alternative for SPECT
imaging for the work-up of selected patients with known or sus-
pected CAD. The comparison of perfusion-CMR with the entire
SPECT population suggests CMR superiority over SPECT, which
warrants further evaluation in larger trials.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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Suppurative bacterial myocarditis: echocardiographic and pathological
findings
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A 45-year-old man was admitted
with anorexia, weight loss, and
rigors. Examination revealed a
tachycardia (126 bpm), hypotension
(86/50 mmHg), and a fever
(39.58C). He was cachectic with
tattoos, piercings, and clinically
dehydrated. Investigations revealed
a normocytic anaemia (Hb 8.6 g/
dL), neutrophilia of 11.31 109/L,
and elevated C-reactive protein
(.160 mg/L). Chest X-ray was
normal. ECG revealed a broadened
QRS complex and non-specific
inferolateral T wave inversion
(Panel A). Intravenous fluid and
co-amoxiclav were commenced
but the patient rapidly developed
severe pulmonary oedema. Echo-
cardiography demonstrated
global severely impaired left ven-
tricular systolic function with
unusual thickening of the papillary
muscles (Panels D–F). The patient
initially improved with CPAP,
diuretics, and antibiotics, but
12 h later developed pulseless
ventricular tachycardia (Panel A)
from which it was impossible to
resuscitate him. Post-mortem
revealed microabscesses contain-
ing gram-positive cocci (Panel C)
throughout the left ventricular
myocardium with confluent col-
lections in the lateral wall and
both inferomedial and anterolat-
eral papillary muscles (Panel B, arrows). The rest of the heart, including valves and endocardium, and other organs were normal. Non-paravalvular
bacterial myocardial abscesses are rarely diagnosed ante-mortem. They are thought to occur following bacteraemia and to be more common in the
immunocompromised. Staphylococcus aureus is the most frequently isolated bacterium and death is usually due to intractable dysrhythmias, cardiac
failure, tamponade, or fistulae. Diagnosis is dependent on a high clinical suspicion in septic patients with severe heart failure. Imaging and ECG
changes are usually non-specific. However, in this case, transthoracic echocardiography demonstrated abnormalities consistent with the post-mortem
findings.
Panel A. ECG demonstrated non-specific broadening of the QRS complexes and inferolateral T wave inversion. This degenerated 12 h after admis-
sion into ventricular tachycardia from which it was not possible to resuscitate the patient.
Panel B. Post-mortem specimen demonstrates myocardial abscesses that are confluent in the lateral wall and both papillary muscles (arrows).
Panel C. Histological samples taken from the areas of abscess demonstrate the presence of gram-positive cocci.
Panels D and F. Parasternal long axis and apical four chamber views demonstrate thickening of anterolateral papillary muscle (arrow), which had
abnormal function and was associated with moderate mitral regurgitation.
Panel E. Parasternal short-axis view at same level as pathology specimen (Panel B) demonstrates areas of thickening and brightness in the myocar-
dium consistent with the pathological findings.
See online supplementary material available at European Heart Journal online for a colour version of this figure.
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